Remote regulatory assessments: Pharma, device groups want more details on FDA guidance

Regulatory NewsRegulatory NewsAudit/inspectionComplianceMedical DevicesNorth AmericaPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/Policy